A 52-year-old woman from Delhi presents with vaginal bleeding and pelvic pain. Cervical biopsy confirms squamous cell carcinoma. MRI pelvis shows a 5 cm cervical lesion with bilateral parametrial invasion extending to the pelvic sidewall. CT chest and abdomen are normal. Serum creatinine is 2.8 mg/dL with bilateral hydronephrosis on imaging. What is the most appropriate first-line treatment for this patient?

Explanation

## Management of Locally Advanced Cervical Cancer (LACC) ### Stage Assignment This patient has: - Tumor size: **5 cm** (>4 cm = IB2) - **Bilateral parametrial invasion extending to pelvic sidewall** - **Bilateral hydronephrosis** (indicates ureteral obstruction) This is **Stage IIIB** cervical cancer (pelvic sidewall involvement and/or hydronephrosis). **Key Point:** Hydronephrosis in the context of cervical cancer is a hallmark of Stage IIIB and indicates advanced disease with ureteral obstruction from tumor invasion. ### Treatment Algorithm for Locally Advanced Cervical Cancer ```mermaid flowchart TD A[Locally Advanced Cervical Cancer<br/>Stage IB2-IVA]:::outcome --> B{Suitable for<br/>radical surgery?}:::decision B -->|No| C[CCRT with cisplatin<br/>+ brachytherapy]:::action B -->|Yes| D{Tumor size<br/>and extent?}:::decision D -->|Stage IB2-IIA<br/>selected cases| E[Radical hysterectomy<br/>+ lymphadenectomy]:::action D -->|Stage IIB-IIIB| C C --> F[Brachytherapy boost]:::action F --> G[Disease control]:::outcome E --> G ``` ### Why CCRT Is the Gold Standard for This Patient | Feature | Consideration | |---------|---------------| | **Tumor size** | 5 cm (>4 cm) — large, not suitable for surgery alone | | **Parametrial invasion** | Bilateral, extending to pelvic sidewall — extensive local spread | | **Hydronephrosis** | Indicates advanced disease; surgery would be morbid | | **Stage** | IIIB — beyond the scope of primary surgical resection | | **Evidence** | CCRT + brachytherapy is the standard of care for Stage IB2–IVA [cite:GOG 165, RTOG 90-01] | **High-Yield:** For **Stage IB2 and beyond**, concurrent chemoradiotherapy (CCRT) with cisplatin is the standard of care. Surgery is reserved for early-stage disease (IA–IIA) without extensive parametrial involvement. **Mnemonic: LACC Management** — **CCRT** - **C**oncurrent chemotherapy (cisplatin 40 mg/m² weekly × 5–6 weeks) - **C**ombined with external beam radiotherapy (EBRT) - **R**adiation to pelvis (45–50 Gy) + parametria - **T**hen brachytherapy boost (intracavitary, 20–30 Gy to point A) ### Rationale for CCRT Over Surgery 1. **Pelvic sidewall involvement:** Tumor extension to the pelvic sidewall makes complete surgical resection impossible without severe morbidity (ureteral injury, vascular injury). 2. **Hydronephrosis:** Indicates advanced ureteral obstruction; surgery would not address the underlying pathology as effectively as radiation. 3. **Bilateral parametrial invasion:** Extensive disease requiring multimodal therapy. 4. **Evidence:** GOG 165 and RTOG 90-01 demonstrated superior survival with CCRT + brachytherapy vs. radiotherapy alone in LACC. **Clinical Pearl:** Cisplatin acts as a radiosensitizer and improves local control and survival in LACC. Dose is typically 40 mg/m² weekly during the 5–6 week course of EBRT. ### Why Not Other Options? - **Radical hysterectomy:** Inappropriate for Stage IIIB disease with pelvic sidewall involvement; surgery cannot achieve negative margins and would incur unacceptable morbidity. - **Neoadjuvant chemotherapy + surgery:** No survival benefit over CCRT + brachytherapy for LACC; delays definitive local therapy. - **EBRT alone:** Inferior outcomes compared to CCRT + brachytherapy; chemotherapy improves local control and overall survival. [cite:GOG 165, RTOG 90-01; Park 26e Ch 13; Berek & Hacker 6e Ch 8]